Heart Failure CONTINUUM OF CARE

The multidisciplinary Heart Failure Program provides expert medical management, advanced surgical care and comprehensive rehabilitation for adult and pediatric patients at all stages of heart failure. We are a world leader in mechanical circulatory support and heart transplantation.

The Center for Circulatory Support houses our internationally recognized ventricular assist device (VAD) program. As one of the few programs worldwide that participates in nearly every VAD-related investigational and FDA-approved clinical trial, our patients have access to next-generation devices and technologies that extend post-implant survival and improve outcomes. A world leader in VAD research and development, the Frankel CVC is a regional and national referral center for adult and pediatric patients with end-stage heart failure or cardiogenic shock. To continue to advance the care of critically ill patients with heart failure, we have partnered with the International Consortium of Circulatory Assist Clinicians to create VAD-C,™ a certification program for clinicians that elevates the quality of care received by VAD patients.

The University of Michigan is the birthplace of extracorporeal membrane oxygenation (ECMO). Our Extracorporeal Life Support Organization (ELSO) Gold Certified Center of Excellence ECMO program provides ECMO across the entire lifespan. We care for approximately 150 ECMO patients annually in five ICUs across U-M Health; 50% of these patients are housed in the Frankel CVC. A team of ECMO-certified critical care nurses and respiratory therapists provide 24/7 in-house ECMO coverage, emergently responds to ECMO needs anywhere on our main hospital campus, and partners with Survival Flight to cannulate and transport critically ill patients to U-M Health from outside facilities.

The internationally-recognized U-M Health Adult Heart Transplant Program is implementing initiatives to expand the volume of heart transplants and reduce transplant waitlist time. With recent advancements in

READ HOW her heart stopped more than 25 times. ECMO saved her life: michmed.org/GyzZg oral antiviral therapy we have initiated a new protocol that allows select patients to accept hearts from donors with active hepatitis C infection and be treated postoperatively to fully eradicate any potential transmission of the virus. Our recent acquisition of the TransMedics® Organ Care system, which preserves donor hearts longer, allows utilization of donor hearts from distances that were previously prohibitive. We are also the first center in Michigan to create an infrastructure for donation following circulatory death (DCD), which allows a heart to be transplanted from a donor who has been declared dead using circulatory criteria but does not meet formal brain death criteria.

Our renowned specialists provide advanced treatment for cardiac sarcoidosis, transthyretin amyloidosis, and hypertrophic obstructive cardiomyopathy. These rare, difficult-to-diagnose conditions require unique expertise and imaging studies. Early referral and diagnosis allows us to offer treatment options not available at lessspecialized centers and optimizes patient outcomes. Our robust clinical trials program provides early access to options such as tafamidis, the only FDA-approved medication to treat transthyretin amyloid cardiomyopathy. The Frankel CVC was the first enrolling site globally and the only site in Michigan for the ATTR-ACT clinical trial of this groundbreaking therapy.

The Frankel CVC offers personalized treatment plans for patients with heart failure with preserved ejection fraction, or HFpEF. We are the only site in Michigan participating in the RESPONDER and BALANCE-HF clinical trials which offer breakthrough device-based care options for this challenging patient population.

A unique U-M Health inpatient heart failure service at Chelsea Hospital, in partnership with Trinity Health gives patients access to Frankel CVC heart failure specialists, closer to home. The program provides intensive education and support to patients and family members during their stay and after discharge.

For information about our many active clinical trials, visit UMHealthResearch.org

AWARDED DISEASE-SPECIFIC CARE CERTIFICATION FOR VENTRICULAR ASSIST DEVICES BY THE JOINT COMMISSION IN 2008 AND CONSISTENTLY RECERTIFIED SINCE

1,360 U-M VAD TICKER

1,360 VADs IMPLANTED AND COUNTING SINCE 1996

HIGH PERFORMANCE RECOGNITION FOR HEART FAILURE

5 YEAR VAD SURVIVAL NEARING 60% WITH HEARTMATE 3 VAD

990 HEART TRANSPLANTS SINCE 1994